All Stories

  1. Oncostatin M: A mysterious cytokine in cancers

    Article • International Immunopharmacology, November 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  2. Immunoreactivity pattern of monoclonal antibodies against Hepatitis B vaccine with global Hepatitis B virus genotypes

    Article • Clinica Chimica Acta, November 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  3. Small-Molecule Inhibitors Targeting Receptor Tyrosine Kinases in Cancer

    Article • October 2020, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  4. IL-10-producing B cells play important role in the pathogenesis of recurrent pregnancy loss

    Article • International Immunopharmacology, October 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  5. Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy

    Article • Nanomedicine Nanotechnology Biology and Medicine, October 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  6. An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein

    Article • Human Vaccines & Immunotherapeutics, July 2020, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  7. CDK1 in Breast Cancer: Implications for Theranostic Potential

    Article • Anti-Cancer Agents in Medicinal Chemistry, July 2020, Bentham Science Publishers

    Dr Mohammad Hojjat-farsangi, Gholamreza Azizi, Hamed Mohammadi

  8. Tumor associated macrophages in the molecular pathogenesis of ovarian cancer

    Article • International Immunopharmacology, July 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  9. ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells

    Article • Biomedicines, June 2020, MDPI AG

    Dr Mohammad Hojjat-farsangi

  10. Concomitant blockade of A2AR and CTLA‐4 by siRNA‐loaded polyethylene glycol‐chitosan‐alginate nanoparticles synergistically enhances antitumor T‐cell responses

    Article • Journal of Cellular Physiology, June 2020, Wiley

    Dr Mohammad Hojjat-farsangi

  11. Nanomedicine for improvement of dendritic cell-based cancer immunotherapy

    Article • International Immunopharmacology, June 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  12. Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer

    Article • Pathology - Research and Practice, May 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  13. Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression

    Article • International Journal of Biological Macromolecules, April 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  14. PD-L1/PD-1 axis as a potent therapeutic target in breast cancer

    Article • Life Sciences, April 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  15. Identification of genes and miRNAs associated with angiogenesis, metastasis, and apoptosis in colorectal cancer

    Article • Gene Reports, March 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  16. The Association between Inflammatory Cytokines and miRNAs with Slow Coronary Flow Phenomenon

    Article • Iranian Journal of Allergy Asthma and Immunology, February 2020, Knowledge E

    Dr Mohammad Hojjat-farsangi

  17. E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions

    Article • Clinica Chimica Acta, November 2019, Elsevier

    Dr Mohammad Hojjat-farsangi

  18. Blockage of immune checkpoint molecules increases T‐cell priming potential of dendritic cell vaccine

    Article • Immunology, October 2019, Wiley

    Dr Mohammad Hojjat-farsangi

  19. Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer

    Article • Prostaglandins & Other Lipid Mediators, October 2019, Elsevier

    Dr Mohammad Hojjat-farsangi

  20. Oxidative stress, inflammatory settings, and microRNA regulation in the recurrent implantation failure patients with metabolic syndrome

    Article • American Journal Of Reproductive Immunology, August 2019, Wiley

    Dr Mohammad Hojjat-farsangi

  21. Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway

    Article • International Journal of Biological Macromolecules, July 2019, Elsevier

    Dr Mohammad Hojjat-farsangi

  22. S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy

    Article • Molecular Diagnosis & Therapy, May 2019, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  23. Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior

    Article • The American Journal of Surgical Pathology, March 2019, Wolters Kluwer Health

    Dr Mohammad Hojjat-farsangi

  24. Metabolic syndrome mediates proinflammatory responses of inflammatory cells in preeclampsia

    Article • American Journal Of Reproductive Immunology, February 2019, Wiley

    Dr Mohammad Hojjat-farsangi

  25. CD73 as a potential opportunity for cancer immunotherapy

    Article • Expert Opinion on Therapeutic Targets, December 2018, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  26. Promising immunotherapy: Highlighting cytokine‐induced killer cells

    Article • Journal of Cellular Biochemistry, December 2018, Wiley

    Dr Mohammad Hojjat-farsangi

  27. Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis

    Article • Journal of Cellular Physiology, December 2018, Wiley

    Dr Mohammad Hojjat-farsangi

  28. Smac mimetics as novel promising modulators of apoptosis in the treatment of breast cancer

    Article • Journal of Cellular Biochemistry, December 2018, Wiley

    Dr Mohammad Hojjat-farsangi

  29. Polymorphism of Foxp3 gene affects the frequency of regulatory T cells and disease activity in patients with rheumatoid arthritis in Iranian population

    Article • Immunology Letters, December 2018, Elsevier

    Dr Mohammad Hojjat-farsangi

  30. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer

    Article • Biomedicine & Pharmacotherapy, December 2018, Elsevier

    Dr Mohammad Hojjat-farsangi

  31. The role of DEAD-box RNA helicase p68 (DDX5) in the development and treatment of breast cancer

    Article • Journal of Cellular Physiology, November 2018, Wiley

    Dr Mohammad Hojjat-farsangi

  32. The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia

    Article • Journal of Cellular Physiology, October 2018, Wiley

    Dr Mohammad Hojjat-farsangi

  33. Altered T-cell subpopulations in recurrent pregnancy loss patients with cellular immune abnormalities

    Article • Journal of Cellular Physiology, September 2018, Wiley

    Dr Mohammad Hojjat-farsangi

  34. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib

    Article • PLoS ONE, June 2018, PLOS

    Dr Mohammad Hojjat-farsangi

  35. Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice

    Article • Journal of Cellular Physiology, May 2018, Wiley

    Gholamreza Azizi, Fatemeh Atyabi, Dr Mohammad Hojjat-farsangi

  36. First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells

    Article • Leukemia, March 2018, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  37. Kisspeptin serum levels in acute myocardial infarction patients and healthy individuals

    Article • Biomedical Research and Therapy, March 2018, Biomedical Research and Therapy

    Abdolreza Sotoodeh jahromi , Dr Mohammad Hojjat-farsangi

  38. Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells

    Article • PLoS ONE, February 2018, PLOS

    Dr Mohammad Hojjat-farsangi

  39. Nanoparticles in cancer therapy

    Article • Immunology Letters, October 2017, Elsevier

    Hamed Mohammadi, Dr Mohammad Hojjat-farsangi

  40. Construction of a hepatitis B virus neutralizing chimeric monoclonal antibody recognizing escape mutants of the viral surface antigen (HBsAg)

    Article • Antiviral Research, August 2017, Elsevier

    Dr Mohammad Hojjat-farsangi

  41. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer

    Article • Journal of Cellular Physiology, May 2017, Wiley

    Hamed Mohammadi, Dr Mohammad Hojjat-farsangi

  42. Recent advances in targeting mTOR signaling pathway using small molecule inhibitors

    Article • Journal of Drug Targeting, October 2016, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  43. Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy

    Article • Current Drug Targets, September 2016, Bentham Science Publishers

    Dr Mohammad Hojjat-farsangi

  44. Application of nanomedicine for crossing the blood–brain barrier: Theranostic opportunities in multiple sclerosis

    Article • Journal of Immunotoxicology, July 2016, Taylor & Francis

    Mousa Mohammadnia-Afrouzi, Dr Mohammad Hojjat-farsangi

  45. Mechanisms of tumor cell resistance to the current targeted-therapy agents

    Article • Tumor Biology, May 2016, Springer Science + Business Media

    Abdolreza Sotoodeh jahromi , Dr Mohammad Hojjat-farsangi

  46. Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia

    Article • Tumor Biology, April 2016, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  47. Sero-Epidemiological Study of Hepatitis E Virus among Thalassemia as High Risk Patients: A Cross-Sectional Survey in Jahrom, Southern, Iran

    Article • Global Journal of Health Science, February 2016, Canadian Center of Science and Education

    Abdolreza Sotoodeh jahromi , Dr Mohammad Hojjat-farsangi

  48. Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia

    Article • PLoS ONE, November 2015, PLOS

    Dr Mohammad Hojjat-farsangi

  49. Association of Tumor Growth Factor-β and Interferon-γ Serum Levels With Insulin Resistance in Normal Pregnancy

    Article • Global Journal of Health Science, September 2015, Canadian Center of Science and Education

    Abdolreza Sotoodeh jahromi , Dr Mohammad Hojjat-farsangi

  50. Lack of Association Between rs17568 Polymorphism in OX40 Gene and Myocardial Infarction, Southern of Iran

    Article • Global Journal of Health Science, September 2015, Canadian Center of Science and Education

    Abdolreza Sotoodeh jahromi , Dr Mohammad Hojjat-farsangi

  51. Ibrutinib-A double-edge sword in cancer and autoimmune disorders

    Article • Journal of Drug Targeting, September 2015, Taylor & Francis

    Abdolreza Sotoodeh jahromi , Dr Mohammad Hojjat-farsangi

  52. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances

    Article • Journal of Drug Targeting, July 2015, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  53. Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy

    Article • Tumor Biology, July 2015, Springer Science + Business Media

    Mousa Mohammadnia-Afrouzi, Dr Mohammad Hojjat-farsangi

  54. The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia

    Article • Future Oncology, May 2015, Future Medicine

    Dr Mohammad Hojjat-farsangi

  55. Novel and emerging targeted-based cancer therapy agents and methods

    Article • Tumor Biology, February 2015, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  56. The receptor tyrosine kinase ROR1 – An oncofetal antigen for targeted cancer therapy

    Article • Seminars in Cancer Biology, December 2014, Elsevier

    Dr Mohammad Hojjat-farsangi

  57. The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies

    Article • British Journal of Haematology, November 2014, Wiley

    Dr Mohammad Hojjat-farsangi

  58. Ligation of human Fc receptor like-2 by monoclonal antibodies down-regulates B-cell receptor-mediated signalling

    Article • Immunology, October 2014, Wiley

    Dr Mohammad Hojjat-farsangi

  59. Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

    Article • International Journal of Molecular Sciences, August 2014, MDPI AG

    Dr Mohammad Hojjat-farsangi

  60. Frequency analysis of HLA class I alleles in Iranian patients with progressive and non-progressive chronic lymphocytic leukemia

    Article • Human Immunology, February 2014, Elsevier

    Dr Mohammad Hojjat-farsangi

  61. The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells

    Article • PLoS ONE, October 2013, PLOS

    Dr Mohammad Hojjat-farsangi

  62. Construction and characterization of a new chimeric antibody against HER2

    Article • Immunotherapy, July 2013, Future Medicine

    Dr Mohammad Hojjat-farsangi

  63. Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia

    Article • Experimental Hematology, July 2013, Elsevier

    Dr Mohammad Hojjat-farsangi

  64. Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia

    Article • Cytokine, June 2013, Elsevier

    Dr Mohammad Hojjat-farsangi

  65. Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells

    Article • PLoS ONE, April 2013, PLOS

    Dr Mohammad Hojjat-farsangi

  66. Increased Frequency of CD8+and CD4+Regulatory T Cells in Chronic Lymphocytic Leukemia: Association with Disease Progression

    Article • Cancer Investigation, January 2013, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  67. Dishevelled Proteins of Wnt Signaling Pathways Are Highly Expressed in Chronic Lymphocytic Leukemia

    Article • Blood, November 2012, American Society of Hematology

    Dr Mohammad Hojjat-farsangi

  68. 162 Investigation of TLR7/8 and 9 Agonists and CD40-ligand Costimulation on EBV Transformation of B Cells of Chronic Lymphocytic Leukemia

    Article • European Journal of Cancer, July 2012, Elsevier

    Dr Mohammad Hojjat-farsangi

  69. Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein

    Article • Journal of Clinical Immunology, March 2012, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  70. Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis

    Article • The Journal of Experimental Medicine, February 2012, Rockefeller University Press

    Dr Mohammad Hojjat-farsangi

  71. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells

    Article • Leukemia, January 2012, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  72. ROR1 Isoforms Are Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) - a Survival Factor for CLL Cells

    Article • Blood, November 2011, American Society of Hematology

    Dr Mohammad Hojjat-farsangi

  73. 1.7 Telomere Length and Expression of Human Telomerase Reverse Transcriptase Splice Variants in Chronic Lymphocytic Leukemia

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2011, Elsevier

    Dr Mohammad Hojjat-farsangi

  74. 9209 POSTER Unbalanced Frequency of Regulatory T Cells in Different Subsets of Chronic Lymphocytic Leukemia

    Article • European Journal of Cancer, September 2011, Elsevier

    Dr Mohammad Hojjat-farsangi

  75. Ror1 Targeting Monoclonal Antibodies Induced Apoptosis of Chronic Lymphocytic Leukemia Cells– A Potential Novel Therapeutic Approach

    Article • Blood, November 2010, American Society of Hematology

    Dr Mohammad Hojjat-farsangi

  76. Expression Profile of Galectin-1 and Galectin-3 Molecules in Different Subtypes of Chronic Lymphocytic Leukemia

    Article • Cancer Investigation, June 2010, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  77. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia

    Article • Cancer Science, December 2009, Wiley

    Dr Mohammad Hojjat-farsangi

  78. Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia

    Article • Leukemia & Lymphoma, October 2009, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  79. Human leukocyte antigen class II allele association to disease progression in Iranian patients with chronic lymphocytic leukemia

    Article • Human Immunology, October 2008, Elsevier

    Dr Mohammad Hojjat-farsangi

  80. Analysis of the immunoglobulin heavy chain variable region gene expression in Iranian patients with chronic lymphocytic leukemia

    Article • Leukemia & Lymphoma, January 2007, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  81. Assessment of the immune system in 55 Iranian patients with vitiligo

    Article • Journal of the European Academy of Dermatology and Venereology, November 2005, Wiley

    Dr Mohammad Hojjat-farsangi